- Patskovsky, Y., Natarajan, A., Patskovska, L. et al. Molecular mechanism of phosphopeptide neoantigen immunogenicity. Nat Commun 14, 3763 (2023).
- Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S., George, M. M., Venkatesh, D., Ghosh, A., Hoyos, D., Molvi, Z., Kamaz, B., Marneth, A. E., Duke, W., Leventhal, M. J., Jan, M., … Merghoub, T. (2022). Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science translational medicine, 14(649), eaba4380.
- Salomé, B., Sfakianos, J. P., Ranti, D., Daza, J., Bieber, C., Charap, A., Hammer, C., Banchereau, R., Farkas, A. M., Ruan, D. F., Izadmehr, S., Geanon, D., Kelly, G., de Real, R. M., Lee, B., Beaumont, K. G., Shroff, S., Wang, Y. A., Wang, Y. C., Thin, T. H., … Horowitz, A. (2022). NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer cell, 40(9), 1027–1043.e9.
- Cimen Bozkus, C., Blazquez, A. B., Enokida, T., & Bhardwaj, N. (2021). A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses. STAR protocols, 2(3), 100758.
- Hobbs, G., Cimen Bozkus, C., Moshier, E., Dougherty, M., Bar-Natan, M., Sandy, L., Johnson, K., Foster, J. E., Som, T., Macrae, M., Marble, H., Salama, M., El Jamal, S. M., Zubizarreta, N., Wadleigh, M., Stone, R., Bhardwaj, N., Iancu-Rubin, C., & Mascarenhas, J. (2021). PD-1 inhibition in advanced myeloproliferative neoplasms. Blood advances, 5(23), 5086–5097.
- Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021). Therapeutic cancer vaccines. Nature reviews. Cancer, 21(6), 360–378.
- Bhardwaj, N., Friedlander, P. A., Pavlick, A. C., Ernstoff, M. S., Gastman, B. R., Hanks, B. A., Curti, B. D., Albertini, M. R., Luke, J. J., Blazquez, A. B., Balan, S., Bedognetti, D., Beechem, J. M., Crocker, A. S., D’Amico, L., Danaher, P., Davis, T. A., Hawthorne, T., Hess, B. W., Keler, T., … Fling, S. P. (2020). Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nature cancer, 1(12), 1204–1217.
- Roudko, V., Bozkus, C. C., Orfanelli, T., McClain, C. B., Carr, C., O’Donnell, T., Chakraborty, L., Samstein, R., Huang, K. L., Blank, S. V., Greenbaum, B., & Bhardwaj, N. (2020). Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell, 183(6), 1634–1649.e17. https://doi.org/10.1016/j.cell.2020.11.004
- Cimen Bozkus, C., Roudko, V., Finnigan, J. P., Mascarenhas, J., Hoffman, R., Iancu-Rubin, C., & Bhardwaj, N. (2019). Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer discovery, 9(9), 1192–1207.
- Saxena, M., Sabado, R. L., La Mar, M., Mohri, H., Salazar, A. M., Dong, H., Correa Da Rosa, J., Markowitz, M., Bhardwaj, N., & Miller, E. (2019). Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial. Frontiers in immunology, 10, 725.
- Saxena, M., Balan, S., Roudko, V., & Bhardwaj, N. (2018). Towards superior dendritic-cell vaccines for cancer therapy. Nature biomedical engineering, 2(6), 341–346.
- Saxena, M., & Bhardwaj, N. (2018). Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Trends in cancer, 4(2), 119–137.
- Saxena, M., & Bhardwaj, N. (2017). Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Current opinion in immunology, 47, 35–43.
- Sabado R. L, E. Miller, M. Spadaccia, I. Vengo, F. Hasan, and N. Bhardwaj. Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. 2013. J. Vis. Exp. Aug 1;(78).
- Sabado R.L. and N. Bhardwaj. Dendritic cell immunotherapy. 2013. Ann. NY Acad. Sci. 1284:31-45.
- Janosky M.*, R. L. Sabado*, C. Cruz, I. Vengco, F. Hasan, A. Winer, L. Moy, S. Adams. MAGE-specific T cell detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy. 2014. Journal for Immunotherapy of Cancer. 2:32. * shared first author
- Miller E. and N. Bhardwaj. Advances in dendritic cell immunotherapies for HIV-1 infection. Expert Opin. Biol. Ther. 2014. 14(11):1545-1549
- Miller E.*, M. Spadaccia*, R.L. Sabado*, E. Chertova, J. Bess, C.M. Trubey, R.M. Holman, A. Salazar, J. Lifson, N. Bhardwaj. Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. 2015. Vaccine 33(2):388-395 * shared first author
- Bhardwaj N. and J. Brody. Dendritic cells and lymphoma cells: come together right now. 2015. Blood. 125(1):5-7
- Sabado R.L.*, A. Pavlick*, S. Gnjatic, C.M. Cruz, I. Vengco, F. Hasan, M. Spadaccia, F. Darvishian, L. Chiriboga, R. M. Holman, J. Escalon, C. Muren, C. Escano, E. Yepes, D. Sharpe, J. P. Vasilakos, L. Rolnitzsky, J. Goldberg, J. Mandeli, S. Adams, A. Jungbluth, L. Pan, R. Venhaus, P. A. Ott and N. Bhardwaj. Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High Risk Melanoma. 2015. Can. Immunol. Res. 3(3):278-287 * shared first author
- Sabado R.L. and N. Bhardwaj. Cancer immunotherapy: dendritic-cell vaccines on the move. 2015. Nature. 519(7543):300-301